Sen. Bernie Sanders argues that Novo Nordisk charges Americans substantially higher prices for its drugs than it does for ...

GLP-1 weight-loss drugs, like Ozempic and Wegovy, offer significant health benefits but spark controversy due to their high prices.

GLP-1 weight-loss drugs alleviate obesity as well as provide other health benefits. Yet, they are also the focus of controversy, with the chief executive of Novo Nordisk, the maker of Ozempic and ...

(Reuters) - U.S. Senator Bernie Sanders is set to question Novo Nordisk CEO Lars Jorgensen on Tuesday over the drugmaker's ...

A key study used in securing FDA approval for Wegovy as a lifetime medication for weight loss was based on patients using the ...

In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard ...

(Reuters) - Novo Nordisk (NYSE: NVO )'s blockbuster diabetes drug Ozempic will be eligible for U.S. government's price ...

The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss ...

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are ...

Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...

Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of ...